Simple Summary There are currently no blood biomarkers approved for routine clinical use
in endometrial cancer. Serum human epididymis protein 4 (HE4) is significantly higher in …

Introduction: Endometrial cancer is the most common gynaecological cancer and its
incidence is rising due to increasing obesity rates. We are also seeing an increasing trend of …

Despite the improvement in overall survival for ovarian cancer (OC) patients, a fraction of
patients with advanced-stage disease fails to respond to primary therapy and relapses in …

Introduction Endometrial cancer, one of the most frequent pelvic gynecologic cancer
worldwide, currently has no biomarker used to assess it in daily practice. Nonetheless …

Objective: To date, biomarkers are not routinely used in endometrial cancer diagnosis,
prognosis, and follow-up. The purpose of this study was to evaluate whether serum HE4 was …

Human epididymis protein 4 (HE4) is an important clinical biomarker used for the detection
of epithelial ovarian cancer (EOC). While much is known about the predictive power of HE4 …

Objectives To evaluate the diagnostic and prognostic potential of preoperative serum CA-
125 and HE4 levels in patients with endometrial cancer. Methods Prospective case–control …

Endometrial cancer is the most common genital cancer in high‐resource countries.
Treatment is essentially surgical, but the role of lymphadenectomy in the treatment of low …

The aim of this study was to evaluate for the first time in the literature the role of HE4, at
primary diagnosis, compared to CA125 as an indicator of endometrial cancer (EC) …

Background Endometrial cancer (EC) is the most common malignancy of the female
reproductive tract. Despite years of research, the accurate screening strategy is still not …